Company: GIFLF
Filing Date: 2025-07-30
Form Type: 6-K
Source: 0001104659-25-071915
Chunk: 5

Company: Grifols SA
Filing Date: 2025-07-30
Form: 6-K
Chunk 5
---
ols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition
to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and
for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable
hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. Grifols, with more than 23,800
employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous
innovation, quality, safety, and ethical leadership.

In 2023, Grifols’ economic impact in its core countries of operation
was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company’s class A shares are listed
on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado
Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For more information about Grifols, please visit .

Page 4 of 5

Legal Disclaimer

The facts and figures contained in this report that do not refer to historical data are ‘projections and future hypotheses’. Words and expressions such as ‘believe’, ‘expect’, ‘anticipate’, ‘predict’, ‘hope’, ‘intend’, ‘should’, ‘will try to achieve’, ‘is estimated’, ‘future’ and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or